



22713 U.S. PTO

Docket Number DM-7029 DIV

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV305490193US  
Express Mail Label Number4/8/04  
Date of DepositAddress to: Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-145022387 U.S. PTO  
10/820307

## UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b)(1) is a **divisional** of prior Application No. 09/454,868, filed December 3, 1999.

Applicant (or identifier): BROWN ET AL.

Title: USE OF THE KCNQ2 AND KCNQ3 GENES FOR THE DISCOVERY  
OF AGENTS USEFUL IN THE TREATMENT OF NEUROLOGICAL  
DISORDERS

Enclosed are:

1. ☒ Specification (Including Claims and Abstract) - 37 pages
  2. ☒ Drawings - 7 sheets
  3. Declaration and Power of Attorney
    - a. ☐ Newly executed (original or copy)
    - b. ☒ Copy from a prior application (signed or with indication that original was signed)
      - i. ☐ Deletion of Inventors  
Signed statement attached deleting inventor(s) named in the prior application
  4. ☒ Incorporation By Reference  
The entire disclosure of the prior application, from which a copy of the Declaration and Power of Attorney is supplied under Box 3b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
  5. ☐ Microfiche Computer Program (appendix)
  6. Nucleotide and/or Amino Acid Sequence Submission
    - ☒ Computer Readable Copy
    - ☒ Paper Copy
    - ☒ Statement Verifying Identity of Above Copies
  7. ☒ Preliminary Amendment
  8. ☐ Assignment Papers (Cover Sheet & Document(s))
  9. ☐ English Translation of
  10. ☐ Information Disclosure Statement
  11. ☐ Certified Copy of Priority Document(s)
  12. ☒ Return Receipt Postcard
  13. ☐ Other:
- ☒ The right to elect an invention or species that is different from that elected in parent Application No. 09/454,868 in the event of a restriction or election of species requirement that is identical or substantially similar to that made in said parent application is hereby reserved.

Filing fee calculation:

- ☒ Before calculating the filing fee, please enter the enclosed Preliminary Amendment.  
☒ Before calculating the filing fee, please cancel claims 22, 23 and 24.

Basic Filing Fee							\$	770
Multiple Dependent Claim Fee (\$ 290)							\$	
Foreign Language Surcharge (\$ 130)							\$	
	For	Number Filed		Number Extra		Rate		
Extra Claims	Total Claims	21	-20	1	x	\$ 18	=	\$ 18
	Independent Claims	1	-3	0	x	\$ 86	=	\$
TOTAL FILING FEE							\$	788

- ☒ Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$788. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.


Please address all correspondence to the address associated with Customer No. 23914, which is currently:

Stephen B. Davis  
Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

Please direct all telephone calls to the undersigned at the number given below and all telefaxes to 609-252-4526.

Respectfully submitted,

Date: 4/8/04

  
John A. Lamerdin, Ph.D.  
Attorney for Applicants  
Reg. No. 44,858  
Tel. No. 609-252-3575



CASE DM-7029 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV305490193US  
Express Mail Label Number

4/8/04  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1647

BROWN ET AL.

Examiner: Gucker, S.

APPLICATION NO: 09/454,868

FILED: DECEMBER 3, 1999

FOR: USE OF THE KCNQ2 AND KCNQ3 GENES FOR THE DISCOVERY  
OF AGENTS USEFUL IN THE TREATMENT OF NEUROLOGICAL  
DISORDERS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of December 15, 2003 has a shortened statutory time set to expire on March 15, 2004. A one-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$110 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.


04/12/2004 HALI11 00000017 09454868

01 FC:1251 110.00 DA

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

Date: 4/8/04

  
John A. Lamerdin, Ph.D.  
Attorney for Applicants  
Reg. No. 44,858  
Phone No. 609-252-3575